Components of successful lead generation.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2005-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1568026053828411PMID 15892684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Facts, figures and trends in lead generation.

  2004cited by this paper
• Applications of high-throughput ADME in drug discovery.

  2004cited by this paper
• Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase.

  2004cited by this paper
• Fragment-based lead discovery

  2004cited by this paper
• High-Throughput Screening: Searching for Higher Productivity

  2004cited by this paper
• High content screening applied to large-scale cell biology.

  2004cited by this paper
• 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.

  2004cited by this paper
• Characteristic physical properties and structural fragments of marketed oral drugs.

  2004cited by this paper
• Assessment of the consistency of medicinal chemists in reviewing sets of compounds.

  2004cited by this paper
• Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.

  2004cited by this paper
• Process optimization using combinatorial design principles: parallel synthesis and design of experiment methods.

  2004cited by this paper
• Molecular recognition: the fragment approach in lead generation.

  2004cited by this paper
• Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors.

  2004cited by this paper
• In vitro approaches to evaluate ADMET drug properties.

  2004cited by this paper
• Molecular properties that influence oral drug-like behavior.

  2004cited by this paper
• Time-related differences in the physical property profiles of oral drugs.

  2004cited by this paper
• Privileged structures: applications in drug discovery.

  2004cited by this paper
• Lead generation--enhancing the success of drug discovery by investing in the hit to lead process.

  2003cited by this paper
• Enabling high-throughput discovery.

  2003cited by this paper
• Fluorescence readouts in HTS: no gain without pain?

  2003cited by this paper
• A guide to drug discovery: Hit and lead generation: beyond high-throughput screening

  2003cited by this paper
• Drug research: myths, hype and reality

  2003cited by this paper
• Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists.

  2003cited by this paper
• Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists.

  2003cited by this paper
• Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs.

  2003cited by this paper
• A comparison of physiochemical property profiles of development and marketed oral drugs.

  2003cited by this paper
• Do structurally similar molecules have similar biological activity?

  2002cited by this paper
• Cellular platforms for HTS: three case studies.

  2002cited by this paper
• A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

  2002cited by this paper
• High Throughput Screening 2002: Moving Toward Increased Success Rates

  2002cited by this paper
• Improvement of "hit-to-lead" optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties.

  2002cited by this paper
• Drugs, leads, and drug-likeness: an analysis of some recently launched drugs.

  2002cited by this paper
• Is There a Difference between Leads and Drugs? A Historical Perspective

  2001cited by this paper
• Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery

  2001cited by this paper
• Property-based design: optimization of drug absorption and pharmacokinetics.

  2001cited by this paper
• The long, hard road: drug metabolism in the lifetime of the DMDG

  2001cited by this paper
• Drug-like properties and the causes of poor solubility and poor permeability.

  2000cited by this paper
• The maximal affinity of ligands.

  1999cited by this paper
• Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.

  1998cited by this paper

• Computationally guided design of N4-(2-methyl-2H-indazol-6-yl)-N2-phenylpyrimidine-2,4-diamine inhibitors of EGFR kinase targeting Cys797.

  2026cites this paper
• Computationally guided optimization of the antimalarial activity and physicochemical properties of 2,4-diaminopyrimidines.

  2025cites this paper
• Fragment-Based Drug Discovery: Small Fragments, Big Impact - Success Stories of Approved Oncology Therapeutics.

  2025cites this paper
• Synthesis, Biological Investigation, and Molecular Docking of Novel Benzimidazole‐Hydrazone Hybrids as Potential Anticancer Agent Candidates

  2024cites this paper
• FRAGMENTISE: A user‐friendly, cross‐platform tool to create and analyze comprehensive small‐molecule fragment databases

  2023cites this paper
• The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation

  2023cites this paper
• The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy

  2022cites this paper
• Preparation, biological & cheminformatics-based assessment of N2,N4-diphenylpyrimidine-2,4-diamine as potential Kinase-targeted antimalarials.

  2021cites this paper
• Analysis of drug–protein interaction in bio-inspired microwells

  2019cites this paper
• Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5.

  2019cites this paper
• Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.

  2018cites this paper
• Synthesis, Plasmodium falciparum Inhibitory Activity, Cytotoxicity and Solubility of N2,N4-Disubstituted Quinazoline-2,4-diamines.

  2018cites this paper
• Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.

  2018cites this paper
• An Analysis of Different Components of a High-Throughput Screening Library

  2018cites this paper
• Synthesis and evaluation of the NSCLC anti-cancer activity and physical properties of 4-aryl-N-phenylpyrimidin-2-amines.

  2017cites this paper
• Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.

  2017cites this paper
• Multiobjective Optimization of Biological and Physical Properties in Drug Discovery

  2017cites this paper
• Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power.

  2016cites this paper
• An approach to "escape from flatland": chemo-enzymatic synthesis and biological profiling of a library of bridged bicyclic compounds.

  2016cites this paper
• Lead Generation Based on Compound Collection Screening

  2016cites this paper
• Defining Known Drug Space Using DFT

  2016cites this paper
• Chapter 7 – Fragment-Based Drug Discovery

  2015cites this paper
• Computational Techniques to Support Hit Triage

  2015cites this paper
• Lead Discovery and Lead Modification

  2015cites this paper
• Modern Cancer Drug Discovery

  2014cites this paper
• Begin with the End in Mind

  2014cites this paper
• Etoposide Quinone Is a Covalent Poison of Human Topoisomerase IIβ

  2014cites this paper
• Natural products as lead structures: chemical transformations to create lead-like libraries.

  2014cites this paper
• Relevance of genetic investigation in male infertility

  2014cites this paper
• Quantitative Structure–Activity Relationship (QSAR) Methods for the Prediction of Substrates, Inhibitors, and Inducers of Metabolic Enzymes

  2014cites this paper
• Exploring the biological promiscuity of high-throughput screening hits through DFT calculations.

  2014cites this paper
• Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum.

  2013cites this paper
• Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines

  2013cites this paper
• Identification of potential drug targets in kinetic networks described by ordinary differential equations (Identifizierung von potenziellen Medikamentenzielen in kinetischen Netzwerken beschrieben durch gewöhnliche Differentialgleichungen)

  2013cites this paper
• Assay Considerations for Compound Library Screening

  2013cites this paper
• Towards the Systematic Discovery of Immunomodulatory Adjuvants

  2013cites this paper
• Coping with Unbalanced Class Data Sets in Oral Absorption Models

  2013cites this paper
• Chemical predictive modelling to improve compound quality

  2013cites this paper
• The Impact of Solubility and Dissolution Assessment on Formulation Strategy and Implications for Oral Drug Disposition

  2012cites this paper
• Application of NMR and molecular docking in structure-based drug discovery.

  2012cites this paper
• Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization

  2012cites this paper
• Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

  2012cites this paper
• The impact of training set data distributions for modelling of passive intestinal absorption.

  2012cites this paper
• Exploring inhibition of Pdx 1 , a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum

  2012cites this paper
• Toward Tomorrow's Drugs: The Synthesis of Compound Libraries by Solid‐Phase Chemistry

  2012cites this paper
• Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases

  2012cites this paper
• Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening.

  2011cites this paper
• In-silico ADME models: a general assessment of their utility in drug discovery applications.

  2011cites this paper
• The influence of the 'organizational factor' on compound quality in drug discovery

  2011cites this paper
• Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.

  2011cites this paper
• Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.

  2011cites this paper
• Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin.

  2011cites this paper
• Probing the links between in vitro potency, ADMET and physicochemical parameters

  2011cites this paper
• Structure‐based Drug Metabolism Predictions for Drug Design

  2010cites this paper
• Thousands of chemical starting points for antimalarial lead identification

  2010cites this paper
• Efficient identification of novel leads by dynamic focused screening: PDK1 case stud.

  2010cites this paper
• In silico fragment-based drug design

  2010cites this paper
• High Throughput Screening Approach to Lead Discovery

  2010cites this paper
• Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.

  2010cites this paper
• Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.

  2010cites this paper
• Probing the Probes: Fitness Factors For Small Molecule Tools

  2010cites this paper
• Identification and hit-to-lead optimization of a novel class of CB1 antagonists.

  2010cites this paper
• Enhancements of screening collections to address areas of unmet medical need: an industry perspective.

  2010cites this paper
• Lead Generation Approaches in Drug Discovery

  2010cites this paper
• Overview: Differentiating Issues in the Development of Macromolecules Compared with Small Molecules

  2010cites this paper
• Lead Discovery: The Process

  2010cites this paper
• Cheminformatic tools for medicinal chemists.

  2010cites this paper
• 1 Lead Discovery : The Process

  2010cites this paper
• Comparison of Molecular Fingerprint Methods on the Basis of Biological Profile Data

  2009cites this paper
• A Practical Method for Targeted Library Design Balancing Lead‐like Properties with Diversity

  2009cites this paper
• The influence of lead discovery strategies on the properties of drug candidates

  2009cites this paper
• Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors.

  2009cites this paper
• Hit triage using efficiency indices after screening of compound libraries in drug discovery.

  2009cites this paper
• Turbo similarity searching: Effect of fingerprint and dataset on virtual‐screening performance

  2009cites this paper
• Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds

  2009cites this paper
• Known drug space as a metric in exploring the boundaries of drug-like chemical space.

  2009cites this paper
• Connecting synthetic chemistry decisions to cell and genome biology using small-molecule phenotypic profiling.

  2009cites this paper
• Lead Discovery Using Virtual Screening

  2009cites this paper
• SPREAD—exploiting chemical features that cause differential activity behavior

  2009cites this paper
• The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".

  2008cites this paper
• Helping science to succeed: improving processes in R&D.

  2008cites this paper
• Fragment-Based Drug Discovery

  2008cites this paper
• High-Throughput Screening and Drug Discovery

  2008cites this paper
• Benchmarking the reliability of QikProp. Correlation between experimental and predicted values

  2008cites this paper
• Modern cancer drug discovery: integrating targets, technologies and treatments

  2008cites this paper
• A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.

  2008cites this paper
• Virtual screening of chemical libraries for drug discovery

  2008cites this paper
• The influence of drug-like concepts on decision-making in medicinal chemistry

  2007cites this paper
• Screening Library Selection and High-Throughput Screening Analysis/Triage

  2007cites this paper
• Rational Drug Design of Small Molecule Anticancer Agents: Preclinical Discovery

  2007cites this paper
• 4.18 – Lead Discovery and the Concepts of Complexity and Lead-Likeness in the Evolution of Drug Candidates

  2007cites this paper
• Activation of Inhibitors by Sortase Triggers Irreversible Modification of the Active Site*

  2007cites this paper
• Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists.

  2007cites this paper
• Hit and Lead identification: efficient practices for drug discovery.

  2007cites this paper
• Fragment-based drug discovery: what has it achieved so far?

  2007cites this paper
• Adjuvant chemotherapy for early-stage breast cancer.

  2007cites this paper
• Properties Guiding Drug‐ and Lead‐Likeness

  2007cites this paper
• Designing Compound Subsets: Comparison of Random and Rational Approaches Using Statistical Simulation

  2007cites this paper
• Representing Clusters Using a Maximum Common Edge Substructure Algorithm Applied to Reduced Graphs and Molecular Graphs

  2007cites this paper
• A decade of fragment-based drug design: strategic advances and lessons learned

  2007cites this paper